Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SCN4A | P35499 | 1/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.47 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966470 | 0.76 | SMN1; SMN2 (0.46) | LMNAMAPTPOLBHSD17B10NQO2 | |
| SCHEMBL7519169 | 0.76 | P2RX4 (0.45) | LMNATSHRMAPTPOLBGAA | |
| Biphenyl SCHEMBL11184429 | 0.74 | ALDH1A1 (0.53) | LMNATSHRBCAT2MAPTPARP1 | |
| Biphenyl SCHEMBL6469097 | 0.74 | ALDH1A1 (0.53) | LMNATSHRBCAT2MAPTPARP1 | |
| Biphenyl SCHEMBL473288 | 0.73 | ALDH1A1 (0.60) | LMNATSHRBCAT2MAPTPARP1 | |
| Biphenyl SCHEMBL4593266 | 0.73 | ALDH1A1 (0.60) | LMNATSHRBCAT2MAPTPARP1 | |
| Biphenyl SCHEMBL335359 | 0.73 | ALDH1A1 (0.60) | LMNATSHRBCAT2MAPTPARP1 | |
| Biphenyl SCHEMBL1952613 | 0.73 | ALDH1A1 (0.60) | LMNATSHRBCAT2MAPTPARP1 | |
| SCHEMBL3296716 | 0.72 | TSHR (0.71) | LMNATSHRMAPK1SCN4ASCN5A | |
| Biphenyl SCHEMBL4912411 | 0.72 | LMNA (0.50) | LMNATSHRBCAT2MAPTPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1748988-A1 | A PROCESS FOR THE PREPARATION OF IMINOSTILBENE DERIVATIVES | Milanese, Alberto (IT) | 2007-02-07 | — | — | EP | claimed |
| WO-2005118550-A1 | A PROCESS FOR THE PREPARATION OF IMINOSTILBENE DERIVATIVES | MILANESE ALBERTO (IT) | 2005-12-15 | — | — | WO | claimed |
| WO-2008108639-A1 | CO-CRYSTALLINE FORMS OF CARBAMAZEPINE | AVANTIUM HOLDING B.V. (NL) | 2008-09-12 | — | — | WO | disclosed |
| US-20060094709-A1 | Methods for the treatment of bipolar disorder using carbamazepine | VALIDUS PHARMACEUTICALS LLC | 2006-05-04 | — | — | US | disclosed |
| US-6977253-B2 | Methods for the treatment of bipolar disorder using carbamazepine | SHIRE PHARMACEUTICAL DEVELOPMENT INC. (US) | 2005-12-20 | — | — | US | disclosed |
| US-20050124601-A1 | in extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | VALIDUS PHARMACEUTICALS LLC | 2005-06-09 | — | — | US | disclosed |
| EP-1026158-B1 | Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine | MAX INDIA LTD (IN) | 2003-09-24 | — | — | EP | disclosed |
| US-6245908-B1 | Process for preparing carbamazepine from iminostilbene | MAX INDIA LIMITED (IN) | 2001-06-12 | — | — | US | disclosed |
| EP-1026158-A1 | Process for the preparation of 5-carbamoyl-5H-dibenz(b,f)azepine | Max India Limited (IN) | 2000-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094709-A1 | Methods for the treatment of bipolar disorder using carbamazepine | GABBR2, GABRE, GABBR1 | LMNA 1915/4885TSHR 3689/4885MAPK1 4874/4885 |
| US-20050124601-A1 | in extended release form; initial daily dose is increased in daily increments; can be co-administered with lithium carbonate, sodium valproate, chlorpromazine, olanzapine, lamotrigine, and/or gabapentin | SLC6A1, SLC6A11, GABRE | LMNA 913/4885TSHR 820/4885MAPK1 4713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.